Journal article
Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline
Abstract
Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aimed to systematically review and update the literature on rituximab in lymphoma and CLL, and provide evidence-based consensus guidelines for its rational use. Validated methodology from the Cancer Care …
Authors
Prica A; Baldassarre F; Hicks LK; Imrie K; Kouroukis T; Cheung M; Care TMOTHDSGOTCCOPIE-B
Journal
Clinical Oncology, Vol. 29, No. 1, pp. e13–e28
Publisher
Elsevier
Publication Date
January 2017
DOI
10.1016/j.clon.2016.09.004
ISSN
0936-6555